Vyndaqel Market Report 2026

Vyndaqel Market Overview

• Vyndaqel market size has reached to $1.9 billion in 2025 • Expected to grow to $4.19 billion in 2030 at a compound annual growth rate (CAGR) of 17.1% • Growth Driver: Rising Adoption Of Precision Medicine Driving Growth In The Market • Market Trend: Facility Expansions Driving Growth In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Vyndaqel Market?

Vyndaqel refers to tafamidis, a medication used to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a heart condition caused by the buildup of misfolded transthyretin proteins. It stabilizes the transthyretin protein, preventing its misfolding and accumulation in the heart. Vyndaqel is used to reduce cardiovascular-related deaths and hospitalizations in patients with ATTR-CM. It is also prescribed to improve the quality of life for individuals suffering from this progressive and often fatal disease. The main product types of vyndaqel are vyndaqel (tafamidis 20 mg) and vyndamax (tafamidis 61 mg). Vyndaqel (Tafamidis 20 mg) is a transthyretin stabilizer used to treat transthyretin amyloid polyneuropathy (ATTR-PN) by slowing disease progression. It is used for familial amyloid polyneuropathy (fap) and wild-type or hereditary transthyretin-mediated amyloidosis cardiomyopathy (attr-cm) and is distributed through hospital pharmacies, online pharmacies, and retail pharmacies.

What Is The Vyndaqel Market Growth Forecast?

The vyndaqel market size is expected to see rapid growth in the next few years. It will grow to $4.19 billion in 2030 at a compound annual growth rate (CAGR) of 17.1%. The growth in the forecast period can be attributed to aging population growth, rising awareness of amyloid cardiomyopathy, expansion of specialty cardiology centers, increased genetic testing adoption, growing reimbursement support. Major trends in the forecast period include increasing adoption of transthyretin stabilizers, rising diagnosis of attr cardiomyopathy, expansion of oral therapies for rare cardiac diseases, growing focus on disease-modifying cardiac drugs, increased use of long-term amyloidosis treatment.

Global Vyndaqel Market Segmentation

1) By Product Type: Vyndaqel (Tafamidis 20 mg), Vyndamax (Tafamidis 61 mg) 2) By Disease Type: Familial Amyloid Polyneuropathy (FAP), Wild-Type Or Hereditary Transthyretin-Mediated Amyloidosis Cardiomyopathy (ATTR-CM) 3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies Subsegments: 1) By Vyndaqel (Tafamidis 20 mg): Oral Capsules, Once-Daily Dosing Regimen, Chronic Long-Term Therapy Use 2) By Vyndamax (Tafamidis 61 mg): Oral Capsules, Once-Daily Dosing Regimen, Chronic Long-Term Therapy Use

What Are The Drivers Of The Vyndaqel Market?

The growing adoption of precision medicine is expected to propel the growth of the Vyndaqel market going forward. Precision medicine involves tailoring medical treatment to individual patients based on their genetic, environmental, and lifestyle factors, improving treatment effectiveness and outcomes. The adoption of precision medicine is increasing as more patients and healthcare providers prefer personalized therapies that ensure targeted treatment and better management of chronic diseases. Vyndaqel enhances precision medicine by offering targeted therapy for transthyretin amyloidosis (ATTR), ensuring patients who will benefit most receive the treatment. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration (FDA) approved 16 novel personalized therapies for patients with rare diseases in 2023, up from six in 2022. Therefore, the growing adoption of precision medicine is driving the growth of the vyndaqel industry. The rising healthcare expenditure is expected to propel the growth of the Vyndaqel market going forward. Healthcare expenditure refers to the total financial resources spent on medical goods and services to maintain and improve population health. Healthcare expenditure is rising as an aging population requires more frequent medical care and long-term health services. Higher healthcare expenditure helps expand access to Vyndaqel by enabling greater funding for high-cost therapies and improving the diagnostic and care infrastructure needed for managing transthyretin amyloid cardiomyopathy. For instance, in April 2025, according to the Office for National Statistics, a UK-based government department, between 2023 and 2024, total healthcare spending increased by 6.5% in nominal terms, and by 2.4% in real terms after accounting for inflation. Therefore, the rising healthcare expenditure driving the growth of the Vyndaqel industry.

Key Players In The Global Vyndaqel Market

Major companies operating in the vyndaqel market are Pfizer Inc.

Global Vyndaqel Market Trends and Insights

Major companies operating in the vyndaqel market is focusing on facility expansions to produce active pharmaceutical ingredients, such as transthyretin stabilizing therapeutic to enhance cardiovascular outcomes and reduce hospitalization in patients with ATTR-CM. Transthyretin stabilizing therapeutic refers to a pharmacological agent designed to bind and stabilize transthyretin (TTR) tetramers, preventing their dissociation into misfolded monomers that aggregate and form amyloid deposits. For instance, in November 2024, BridgeBio Pharma, a US-based biopharmaceutical company focused on genetic diseases, launched Attruby (acoramidis), a near-complete (≥90%) transthyretin (TTR) stabilizer designed to address key challenges in transthyretin amyloid cardiomyopathy (ATTR-CM). Attruby (acoramidis) binds and stabilizes TTR tetramers, preventing their dissociation into misfolded monomers that form amyloid deposits in cardiac tissue. The therapy offers significant cardiovascular benefits, including reduction in cardiovascular death and cardiovascular-related hospitalizations, while preserving TTR’s native physiological functions making it an effective treatment for improving patient outcomes and disease management in ATTR-CM.

Regional Insights

North America was the largest region in the vyndaqel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Vyndaqel Market?

The vyndaqel market consists of sales of cardiovascular medications, neuropathy medications, anticoagulants and diuretics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vyndaqel Market Report 2026?

The vyndaqel market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vyndaqel industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.